BioWorld

Oct. 3, 2003

Genetic Model Company GenPath Raises $42.7M In Series B Round

Little more than a year after starting a business based on spontaneous tumor models in mice, GenPath Pharmaceuticals Inc. raised $42.7 million in a Series B financing. (BioWorld Today) Read More

Nuvelo Raises $24.5M For Alfimeprase, In-Licensing

French Scientists Win Where Others Lost, Cloning Robust Rat Colony To Make Drugs Against Major Diseases

Biosyn Eyeing $10M For HIV Product Development Program

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...